Halozyme Therapeutics (NASDAQ:HALO) Shares Up 5.9%

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares were up 5.9% during trading on Wednesday . The stock traded as high as $44.79 and last traded at $43.63. Approximately 653,201 shares traded hands during trading, a decline of 46% from the average daily volume of 1,200,106 shares. The stock had previously closed at $41.21.

Analyst Ratings Changes

A number of research analysts recently weighed in on HALO shares. Benchmark reissued a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday. JMP Securities lowered their price target on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a research report on Wednesday. TD Cowen initiated coverage on shares of Halozyme Therapeutics in a research note on Thursday, February 29th. They set an “outperform” rating and a $54.00 price objective for the company. Finally, TheStreet downgraded shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average price target of $53.14.

Halozyme Therapeutics Price Performance

The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50. The stock has a market capitalization of $5.34 billion, a P/E ratio of 20.13, a P/E/G ratio of 0.47 and a beta of 1.26. The firm has a fifty day moving average of $40.04 and a two-hundred day moving average of $37.99.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. On average, analysts predict that Halozyme Therapeutics, Inc. will post 3.43 EPS for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total transaction of $384,900.00. Following the completion of the sale, the senior vice president now directly owns 168,176 shares in the company, valued at approximately $6,473,094.24. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have sold 30,000 shares of company stock valued at $1,196,800. Insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of Halozyme Therapeutics by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 13,259,514 shares of the biopharmaceutical company’s stock worth $490,072,000 after purchasing an additional 152,870 shares in the last quarter. Artisan Partners Limited Partnership raised its holdings in shares of Halozyme Therapeutics by 3.4% during the third quarter. Artisan Partners Limited Partnership now owns 7,712,874 shares of the biopharmaceutical company’s stock valued at $294,632,000 after acquiring an additional 253,363 shares during the last quarter. TD Asset Management Inc lifted its position in shares of Halozyme Therapeutics by 517.0% in the fourth quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock valued at $73,326,000 after acquiring an additional 1,662,390 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Halozyme Therapeutics by 2.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,736,122 shares of the biopharmaceutical company’s stock worth $64,167,000 after purchasing an additional 37,763 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Halozyme Therapeutics by 9.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,613,113 shares of the biopharmaceutical company’s stock valued at $59,622,000 after purchasing an additional 145,879 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.